Roche (SIX: ROG) is scheduled to hold its investor Pharma Day Monday September 28, 2026, providing updates across the R&D portfolio including three obesity assets that collectively position the company as the credible third-place global obesity competitor behind Eli Lilly and Novo Nordisk. Petrelintide (amylin analog, partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, Phase 3 monotherapy initiation planned late 2026 following ZUPREME-1's 10.7% weight loss at 42 weeks). Enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2). HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties). The Roche Pharma Day coincides with the EASD 2026 Annual Meeting Milan September 28 through October 2, where AstraZeneca will present AZD6234 Phase 2 data, Zealand Pharma will present petrelintide data, and Novo Nordisk will present amycretin and CagriSema updates.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP dual agonist peptide, in Kailera's global Phase 3 KaiNETIC program); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.